NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
QURE
uniQure N.V.
QURE has the edge over NVO overall, supported by stronger modeled upside and stronger fundamentals.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
QURE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Strong |
QURE's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
QURE PE Valuation
QURE has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
QURE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect QURE's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over QURE on earnings quality, reporting a profit while its opponent remains loss making.
QURE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.52 | +$0.86 |
| Q2 2026 | -$4.02 | -$0.11 |
| Q1 2026 | -$3.49 | +$0.89 |
| Q4 2025 | -$3.46 | +$1.46 |
| Q3 2025 | -$4.38 | +$0.57 |
| Q2 2025 | -$3.91 | +$2.01 |
| Q1 2025 | -$4.38 | +$1.82 |
| Q4 2024 | -$4.92 | +$1.55 |
QURE is still losing money, but less than at its worst: $3.52 per share over the past year, against $6.47 at its worst in late 2023.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over QURE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over QURE on profitability, with a higher operating margin.
QURE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.2M | +40% |
| Q2 2026 | $5.8M | +11% |
| Q1 2026 | $3.6M | +127% |
| Q4 2025 | $5.6M | +6.6% |
| Q3 2025 | $3.7M | +62% |
| Q2 2025 | $5.3M | -53% |
| Q1 2025 | $1.6M | -82% |
| Q4 2024 | $5.2M | -22% |
QURE's revenue is recovering but still below its 2021 peak: $5M last quarter, up 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1020% | +359 points |
| Q2 2026 | -894% | -60 points |
| Q1 2026 | -1284% | +1226 points |
| Q4 2025 | -918% | -40 points |
| Q3 2025 | -1379% | +380 points |
| Q2 2025 | -834% | -438 points |
| Q1 2025 | -2510% | -1871 points |
| Q4 2024 | -878% | +45 points |
QURE's operating margin was −1020% last quarter, up 359 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over QURE on cash generation, producing positive trailing cash flow while its opponent burns cash.
QURE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.8M | -$31.5M |
| Q2 2026 | -$29M | +$11.1M |
| Q1 2026 | -$38.4M | +$5.8M |
| Q4 2025 | -$77.7M | -$24.8M |
| Q3 2025 | -$16.3M | +$20.6M |
| Q2 2025 | -$40.2M | -$6.8M |
| Q1 2025 | -$44.2M | +$18.7M |
| Q4 2024 | -$52.9M | -$1.3M |
QURE has burned cash in almost every quarter: −$193M over the past year, against −$154M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over QURE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
QURE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.5% | +3.7M shares |
| 1 year | +19% | +11.4M shares |
| 3 years | +46% | +22.1M shares |
| 5 years | +51% | +23.7M shares |
| Available history | +75% | +29.9M shares |
QURE has 70M diluted shares, up 19% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
QURE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -1.4x | Net Cash |
| Q4 2021 | -1.4x | Net Cash |
QURE has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
QURE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.4 | Neutral |
| Stochastic | 10.8 | Oversold |
QURE's weekly RSI is 41 (neutral) and its Stochastic is 11 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
QURE PE vs Healthcare Sector
| Metric | QURE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
QURE has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
QURE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.0 | 1.3% below |
| 20 week MA | $36.6 | 33% below |
| 50 week MA | $28.6 | 14% below |
| 100 week MA | $24.8 | 0.6% below |
| 200 week MA | $17.3 | 43% above |
QURE has fallen below most of its moving averages, though it's still 43% above its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
QURE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $72.5 | $38.1 | -47% |
| 2021 | $38.1 | $22.3 | -42% |
| 2022 | $22.3 | $23.3 | +4.7% |
| 2023 | $23.3 | $6.77 | -71% |
| 2024 | $6.77 | $17.5 | +158% |
| 2025 | $17.5 | $24.8 | +42% |
| 2026 YTD | $24.8 | $24.6 | -0.7% |
QURE has the edge over NVO on returns for 2026, with the stronger performance.